Navigation Links
CIDP Treated With Plasma-Derived Therapy

Patients with rare, chronic inflammatory demyelinating polyneuropathy (CIDP) depend on plasma donation

ANNAPOLIS, Md., April 24 /PRNewswire/ -- Chronic inflammatory demyelinating polyneuropathy (CIDP) is a debilitating, progressive neurological disorder that results in muscle weakness and fatigue and can severely impair motor skills. According to the GBS/CIDP Foundation International, CIDP affects two to seven individuals per 100,000 worldwide. The rare disease is treated with intravenous immune globulin (IVIG), a plasma-derived therapy that replaces vital missing antibodies in a person's plasma and that is manufactured by member companies of the Plasma Protein Therapeutics Association (PPTA).

As recently reported in the news, William "The Refrigerator" Perry, a former Chicago Bears lineman, has been hospitalized for treatment of CIDP, which has brought this little known disease some recognition and spurred discussion about the illness and how it is treated in the news and among football fans.

IVIG also is the subject of legislation recently introduced in Congress, The Medicare Patient IVIG Access Act (S. 701 and H.R. 2002). The bills seek adequate reimbursement for IVIG therapy in all sites of care and to complete the hollow primary immunodeficiency disease (PIDD) home infusion benefit. If passed, S.701, introduced by Sens. John Kerry (D-MA) and Lamar Alexander (R-TN), and H.R. 2002, introduced by Reps. Steve Israel (D-NY) and Kevin Brady (R-TX), will improve access to treatment and enhance the quality of life for patients who encounter hurdles to accessing their lifesaving therapy.

PIDD is treated by infusing or injecting immune globulin therapy, which works to supplant a damaged or deficient immune system. According to the Immune Deficiency Foundation, the advocacy organization leading the support for the IVIG Access Act, about 55,000 individuals in the U.S. who are antibody deficient receive the therapy.

"IVIG is produced from plasma that is donated by healthy, committed donors across the nation," said Julie Birkofer, PPTA Vice President, North America. Plasma is the straw-colored, liquid portion of whole blood that remains when red blood cells, platelets and other cellular components are removed. It is rich in proteins needed to fight infection, clot blood, and ensure proper lung function.

Source plasma used to produce life-saving therapies like IVIG is donated by healthy, committed individuals at 380 government licensed and International Quality Plasma Program-certified plasma collections centers in the U.S., Europe and Canada.

"Across the country, tens of thousands of individuals rely on plasma protein therapies to treat rare, chronic diseases and disorders, which include hemophilia and other bleeding disorders, primary immunodeficiency diseases, alpha-1 antitrypsin deficiency, Kawasaki disease, and certain autoimmune and neurological disorders like CIDP," said Birkofer. "IVIG is a vital protein replacement therapy that treats diseases that are often life-threatening and always serious and chronic."

To learn more about lifesaving plasma protein therapies, visit To find out how to become a plasma donor and become an important part of saving someone's life, visit Visit for more information about CIDP. For information about primary immunodeficiency disease, visit

The Plasma Protein Therapeutics Association (PPTA) is the trade association and standard setting organization for the world's major producers of plasmaderived and recombinant analog therapies (collectively, "plasma protein therapies"). These therapies are used by more than 1 million people worldwide each year to treat a variety of diseases and serious medical conditions. PPTA members produce over 80 percent of the plasma therapies for the United States market and more than 60 percent worldwide. Some of the critical therapies produced by PPTA members include: blood clotting factors for people with hemophilia, immune globulin intravenous used to prevent infections in people with immune deficiencies and other serious conditions, and alpha1 proteinase inhibitor used to treat people with alpha1antitrypsin deficiency, also known as genetic emphysema.

SOURCE Plasma Protein Therapeutics Association
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. First Patients Treated in India Using CyberKnife Radiosurgery
2. If You Treated an Illinois Workers Compensation Patient or a Patient Covered by an Illinois Automobile Insurance Policy and Your Bill was Reduced by a Discount Pursuant to a First Health or CCN PPO Network, Please Read This Notice Carefully As It Affects
3. Tens of Thousands of Back Pain Patients Overtreated in Six Health Plans, According to HealthCore Study
4. Doctors call for change in how non-active TB in immigrant children treated
5. Teens Undertreated for Substance Abuse
6. Stroke treated significantly faster and just as safely by medical residents
7. Most HIV-Infected Prisoners Go Untreated After Release
8. First Dutch Patients Treated With the Percutaneous MitraClip(R) System
9. Pearly Penile Papule Patients Can Successfully Be Treated with Targeted CO2 Technology at La Jolla Cosmetic Surgery Centre
10. Georgia Ranks Fourth in the Number of Untreated HIV Patients in the United States
11. Penn study: Chances of surviving cardiac arrest depend on where patients are treated
Post Your Comments:
(Date:11/30/2015)... ... 2015 , ... The National Association of Professional Women (NAPW) honors ... Year Circle. She is recognized with this prestigious distinction for leadership in estate sales ... more than 850,000 members and over 200 operating Local Chapters. , “I’m pleased to ...
(Date:11/30/2015)... ... December 01, 2015 , ... Live ... offer individual vision insurance plans on . The multi-carrier insurance exchange ... and review products, allowing consumers to compare, quote and match plans to meet ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... (Meso Foundation) released information for caregivers and held two webinars on topics of ... on demand free of charge at . , With a loved ...
(Date:11/30/2015)... ... November 30, 2015 , ... Thermi™, a ... to announce that its ThermiRFR temperature controlled radiofrequency platform has received CE marking ... radiofrequency platform which uses temperature as a clinical endpoint. The technology has ...
(Date:11/30/2015)... Fla. (PRWEB) , ... November 30, 2015 , ... ... opened the driverless vehicle experience this summer, ushering in a new era of ... percent driverless and electric shuttle, will continue to offer guests an up-close look ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... 1, 2015 Express Scripts (NASDAQ: ESRX ) ... IMMY ) to drive access to a low-cost alternative to ... toxoplasmosis that has been recently priced out of reach for ... systems. --> --> Imprimis ... (a form of folic acid) for $1 per capsule for people ...
(Date:11/30/2015)... 2015 Die MEDTEC Japan ... für Entwicklung und Herstellung medizinischer Geräte, ... 2016 in Tokyo ... Foto:- Foto: ... Logo: --> ...
(Date:11/30/2015)... , December 1, 2015 ... adds "Endometriosis - Pipeline Review, H2 ... overview on therapeutic pipeline of Endometriosis and ... effective counter strategies to gain competitive advantage. ... targets and MOAs to produce first-in-class and ...
Breaking Medicine Technology: